Unilife is beset by luck. Most of it bad. When the Amgen deal...

Unilife is beset by luck. Most of it bad. When the Amgen deal was announced- China had a meltdown and we didn't get the expected SP kick.
Now with the approval of Dupilumab we have a legal patent stouch happening.
Now I know nothing about the patent side or legal side but there is a slight difference in terminology being used today.

Previously it's been all about the PCSK9- https://en.wikipedia.org/wiki/PCSK9, but now the Reuters report following- talks about the IL-4 and IL 13 proteins.
http://www.reuters.com/article/us-regeneron-fda-eczema-idUSKBN16Z25Z

"This drug is really a game changer," said Dr. Emma Guttman-Yassky, Vice Chair of the department of dermatology at Mount Sinai Hospital in New York who conducted clinical trials of dupilumab.

The drug works by blocking the IL-4 and IL-13 proteins involved in the body's immune response that Regeneron and Sanofi believe to be underlying causes of a number of complex conditions.

In a pivotal late stage study, after 16 weeks of treatment with 300 milligrams of Dupixent either weekly or every two weeks.

Some further reading
https://en.wikipedia.org/wiki/PCSK9
https://en.wikipedia.org/wiki/Interleukin_4
https://www.google.com.au/search?q=IL-13 proteins&oq=IL-13 proteins&aqs=chrome..69i57&sourceid=chrome&ie=UTF-8